Literature DB >> 10868672

How was life after treatment of a malignant brain tumour?

P Salander1, A T Bergenheim, R Henriksson.   

Abstract

The malignant glioma is a severe disease with an unfavourable prognosis. Aside from a few case studies, the knowledge of the victimised patients' lives from diagnosis to death is mainly restricted to studies assessing functional status and rating quality of life by means of questionnaires. From a clinician's perspective this knowledge is not sufficient. By introducing the concepts 'time of everyday life' and 'time of disease', the purpose of this paper is to supplement with descriptive knowledge of clinical value. Twenty-eight patients with malignant gliomas and their spouses were followed during the course of the disease by repeated interviews. The time after treatment was then judged as representing, 'time of everyday life' or 'time of disease'. Life after treatment turned out to be quite varied. To slightly more than a third of the patients', life-continuity was lost, experiencing only 'time of disease'. Among the others who were judged to experience 'time of everyday life' and who were of working age, nearly two-thirds were able to resume work or studies on a part-time basis. In the total sample, the mean 'time of everyday life' turned out to be nearly equal to 'time of disease', 6.1 and 5.4 months, respectively. The findings are illustrated by case descriptions and the conceptualisation of time into 'everyday life' and 'disease' is proposed as meriting further study.

Entities:  

Mesh:

Year:  2000        PMID: 10868672     DOI: 10.1016/s0277-9536(00)00002-2

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  20 in total

1.  Measuring clinical benefit: use of patient-reported outcomes (PRO) in primary brain tumor clinical trials.

Authors:  Terri S Armstrong
Journal:  Curr Oncol Rep       Date:  2013-02       Impact factor: 5.075

2.  Views of bereaved relatives about quality of survival after radiotherapy for malignant cerebral glioma.

Authors:  E Davies; C Clarke
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-04       Impact factor: 10.154

3.  Facets and determinants of quality of life in patients with recurrent high grade glioma.

Authors:  A R Giovagnoli; A Silvani; E Colombo; A Boiardi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-04       Impact factor: 10.154

Review 4.  Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials clinical outcome assessment endpoints workshop (October 15, 2014, Bethesda MD).

Authors:  Jennifer L Helfer; Patrick Y Wen; Jaishri Blakeley; Mark R Gilbert; Terri S Armstrong
Journal:  Neuro Oncol       Date:  2016-03       Impact factor: 12.300

Review 5.  Living longer with adult high-grade glioma: setting a research agenda for patients and their caregivers.

Authors:  Bethany Russell; Anna Collins; Michael Dally; Anthony Dowling; Michelle Gold; Michael Murphy; Jennifer Philip
Journal:  J Neurooncol       Date:  2014-07-01       Impact factor: 4.130

6.  Factors influencing quality of life in patients with benign primary brain tumors: prior to and following surgery.

Authors:  Shiow-Luan Tsay; Jui-Yen Chang; Patsy Yates; Kuan-Chia Lin; Shu-Yuan Liang
Journal:  Support Care Cancer       Date:  2010-11-24       Impact factor: 3.603

7.  Odyssey of hope: a physician's guide to communicating with brain tumor patients across the continuum of care.

Authors:  Mark L Rosenblum; Steven Kalkanis; Wendy Goldberg; Jack Rock; Tom Mikkelsen; Sandra Remer; Sarah Whitehouse; David Nerenz
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

Review 8.  Patient reported endpoints for measuring clinical benefit in (high grade glioma) primary brain tumor patients.

Authors:  Terri S Armstrong; Mark R Gilbert
Journal:  Curr Treat Options Oncol       Date:  2014-12

9.  Quality of life and brain tumors: what beyond the clinical burden?

Authors:  Anna Rita Giovagnoli; Rute Flávia Meneses; Antonio Silvani; Ida Milanesi; Laura Fariselli; Andrea Salmaggi; Amerigo Boiardi
Journal:  J Neurol       Date:  2014-03-04       Impact factor: 4.849

10.  Workplace support for employees with cancer.

Authors:  B Nowrouzi; N Lightfoot; K Cote; R Watson
Journal:  Curr Oncol       Date:  2009-09       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.